Schering Corporation

Schering-plough Corporation

Merck Sharp + Dohme Corp.

Pharmacopeia Drug Discovery, Inc.

Scheeing Corporation

Pharmacopeia Inc.

Pietro Mangiaracina

Neng-Yang Shih

Kevin D McCormick

Robert G Aslanian

Christopher W Boyce

Michael Berlin

Stuart B Rosenblum

Mwangi W Mutahi

Wing C Tom

Pauline C Ting

Manuel De Lera Ruiz

Ashit K Ganguly

John J Piwinski

Anil K Saksena

Younong Yu

Daniel M Solomon

Jesse K Wong

Junying Zheng

Chia-Yu Huang

Bo Liang

Rong-qiang Liu

Michael J Green

Bandarpalle B Shankar

Gregory A Reichard

Jianhua Chao

Qingbei Zeng

Henry A Vaccaro

Salem Fevrier

Xiaohong Zhu

Jianhua Cao

Nicholas I Carruthers

Ruiyan Liu

Michael P Kirkup

James M Spitler

Cheryl A Alaimo

Lisa Guise-Zawacki

Andrew Lupo, Jr

Joseph A Kozlowski

Purakkattle J Biju

Huagang Lu

Stephanie Louise Ciesla

Michael Y Berlin

Kevin D Mc Cormick

In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of &#xff;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#xff;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

In its many embodiments, the present invention provides a novel class of naphthene- and indane-type as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective ALPHA2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as &#x3b1;2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the &#x3b1;2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

ALPHA2C adrenoreceptor agonists

Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: 

[object Object]

In its many embodiments, the present invention provides a novel class of indolines as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

&#x3b1;2C adrenoreceptor agonists

Disclosed are novel compounds of the formula  Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a Hreceptor antagonist.

Non-imidazole compounds

Disclosed are novel compounds of the formula wherein Ris benzimidazolone derivative, Mand Mare optionally substituted carbon or nitrogen, Rincludes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Disclosed are novel compounds of the formula wherein Ris optionally substituted benzimidazolyl or a derivative thereof; Ris optionally substituted aryl or heteroaryl; Mand Mare C(R) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Benzimidazole derivatives useful as histamine H3 antagonists

Disclosed are novel compounds of the formulawherein Mis CH or N and Mis C(R) or N; Ris optionally substituted indolyl or an aza derivative thereof; Ris optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a Hreceptor antagonist.

Indole derivatives useful as histamine H3 antagonists

Compound represented by the structural formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or3;

Substituted oximes, hydrazones and olefins as neurokinin antagonists

Compound represented by the structural formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or 3;

Lipoxygenase inhibitors

Growing community of inventors

Monsey, NY, United States of America

Pietro Mangiaracina